Physician Sentiment on XTANDI®

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated 2026-07-13. KOL Pulse reports the physician conversation and does not endorse any product.

Trial 1 · NCT02319837

What do oncologists think of the EMBARK trial (XTANDI®)?

EMBARK — Non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence

FDA APPROVED · Nov 2023FDA-approved November 16, 2023, for non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

Physicians are broadly favorable, with real nuance on EMBARK: 25% of 12 verified physician voices positive, 25% nuanced (praising the result while flagging a caveat), 33% neutral, 17% critical.

25%

33%

17%

Positive 25% Nuanced 25% Neutral 33% Critical 17%

Denominator: 12 distinct verified physician voices across 18 oncologist posts, 2025-10-19 to 2025-10-23. Sponsor: Pfizer

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Primary sources: ClinicalTrials.gov · NCT02319837 · NEJM 2023 — EMBARK (Freedland et al.)

Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med 2023 (EMBARK, NCT02319837).

Physician voices — verbatim

Representative positive voice

High-impact shifting update by @SFreedlandMD on EMBARK: enzalutamide in BCR PCa reduced risk of death by 40%. OS HR 0.59 (95% CI 0.44–0.80); p=.0006. #ESMO25 #ProstateCancer @myESMO @ASCOpost @OncoAlert @OncLive

Toni Choueiri, MD

@DrChoueiri

Representative nuanced voice

Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science

Neeraj Agarwal, MD, FASCO

@neerajaiims

Representative critical voice

#ESMO25 EMBARK Enza+ADT: MFS/OS ⬆️ in HR BCR #ProstateCancer Does this set a new SoC? ❓EMBARK used historic imaging/no #PSMA, limiting true stage Dx ❓Earlier local treatment partially missed ➡️Modern staging needs to reshape who truly benefits @oncodaily @urotoday @laconss

Sabine D. Brookman-May

@brookmans76

Full physician voice list (12)

Physician	Comment (verbatim)	Sentiment	Impressions
Neeraj Agarwal, MD, FASCO @neerajaiims	Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the tea…	Nuanced	11,825
Toni Choueiri, MD @DrChoueiri	High-impact shifting update by @SFreedlandMD on EMBARK: enzalutamide in BCR PCa reduced risk of death by 40%. OS HR 0.59 (95% CI 0.44–0.80); p=.0006. #ESMO25 #ProstateCancer @myESMO @ASCOpost @OncoAlert @OncLive	Positive	4,653
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @CParkMD	⭐️Neeraj and I discuss how the EMBARK study #ESMO25 gives us a path forward for intermittent treatment for certain patients with metastatic hormone sensitive prostate cancer. LOVE this discussion. Full video click here 👉 https://t.co/bohtD…	Positive	4,295
Rashid K. Sayyid @RKSayyid	EMBARK: Final OS data for ENZA combo & ENZA mono vs leuprolide 📌ENZA combo: 40% ⬇️ OS (HR 0.6, p<0.01) 🔹ENZA mono: 17% ⬇️ OS (NS; HR 0.83, p=0.2) 🔹Times to new anti-neoplastic Tx, SSE, PFS2 all sig favored both ENZA combo & mono 📛 No new sa…	Positive	2,534
Sabine D. Brookman-May @brookmans76	#ESMO25 EMBARK Enza+ADT: MFS/OS ⬆️ in HR BCR #ProstateCancer Does this set a new SoC? ❓EMBARK used historic imaging/no #PSMA, limiting true stage Dx ❓Earlier local treatment partially missed ➡️Modern staging needs to reshape who truly bene…	Negative	1,914
Zach Klaassen @zklaassen_md	EMBARK OS data helping with "Enza combo vs Enza mono" question - Enza combo: ADT side effects - Enza mono: s3x preservation, but gynecomastia Likely, Enza combo for most/all with 40% ⬇️ mortality risk @urotoday #ESMO25	Nuanced	1,718
Ravi A Madan M.D. @Dr_RaviMadan	#EMBARK data is important for some BCR pts but not MOST #BCR #ProstateCancer pts #ESMO25 This a biomarker selected group! #PSA DT defines WHO benefits (diminishes beyond PSADT 6 mos) ⚠️Cancer specific mortality @10yrs for all BCR pts is…	Nuanced	1,588
Oncology Brothers @OncBrothers	3. #EMBARK: Enzalutamide in high risk biochemical recurrent Prostate Ca vs. ADT alone - mOS ⬆️ with Enzalutamide + ADT improved - 8yr mOS 78.9% vs. 69.5% (HR: 0.60) - Enza alone is not superior to ADT alone in OS 5/11 https://t.co/Gjywf…	Neutral	656
Prof. Dr. Ahmet Dirican @dr_dirican	Mixed results for #Enzalutamide in non-metastatic #ProstateCancer 🧬 At #ESMO25: 🔹 ENZARAD (LBA86): No MFS benefit when added to ADT + RT in high-risk localized disease (HR 0.88, p = 0.34). 🔹 EMBARK (LBA87): Significant OS improvement with …	Negative	243
Tuğba Başoğlu, MD @tugbawitter	🚨 Breaking from #ESMO25 \| EMBARK Trial Update Enzalutamide + ADT significantly improves overall survival in high-risk biochemically recurrent #ProstateCancer vs ADT alone! 🧪 HR: 0.597 📈 8-year OS: • Enza combo: 78.9% • ADT alone: 69.5% 🧬 R…	Neutral	230
Dries Develtere @DriesDeveltere	My critical analysis of the EMBARK Final Results in @NEJM and presented at #ESMO25 OS benefit with a catch https://t.co/VGhkPXYbPr	Neutral	77
tombal @BertrandTOMBAL	Maybe we should ask the patient and clearly explain pro and cons…	Neutral	74

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Trial 2 · NCT04419402

What do oncologists think of the ENZA-p trial (XTANDI®)?

ENZA-p — Metastatic castration-resistant prostate cancer — enzalutamide + 177Lu-PSMA-617 (investigational combination)

INVESTIGATIONAL COMBINATIONThe enzalutamide + 177Lu-PSMA-617 combination studied in ENZA-p is investigational and not FDA-approved. Enzalutamide monotherapy is separately FDA-approved for metastatic castration-resistant prostate cancer.

Physicians are broadly favorable, with real nuance on ENZA-p: 16% of 13 verified physician voices positive, 15% nuanced (praising the result while flagging a caveat), 69% neutral, 0% critical.

16%

15%

69%

Positive 16% Nuanced 15% Neutral 69% Critical 0%

Denominator: 13 distinct verified physician voices across 17 oncologist posts, 2025-02-13 to 2025-04-25. Sponsor: ANZUP Cancer Trials Group (ANZUP 1901)

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Primary sources: ClinicalTrials.gov · NCT04419402 · Lancet Oncology 2024 — ENZA-p (Emmett et al.)

Emmett L, Subramaniam S, Crumbaker M, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2024 (NCT04419402).

Physician voices — verbatim

Representative positive voice

🔥Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901) ⏩ @ASCO #GU25: Adding [177Lu]Lu-PSMA-617 to enzalutamide improves survival & quality… https://t.co/cvLIwa3xUH

Emre Yekedüz

@yekeduz_emre

Representative nuanced voice

Curious to see differences between 2 doses and 4 doses of 177-Lu-PSMA-617 But very encouraging results, combination therapy will become a new standard for mCRPC

Tanya Dorff

@TDorffOnc

Full physician voice list (13)

Physician	Comment (verbatim)	Sentiment	Impressions
Michael Hofman @DrMHofman	New Frontiers in PSMA Radioligand Therapy Is this the "hottest" session at @ASCO #ASCO25 ?? ■ VIOLET: First-in-human trial of Terbium-161 ■ BULLSEYE: Lu-PSMA in oligo-metastatic disease ■ ENZA-p: Biomarkers @pros_tic @PCF_Science	Neutral	4,570
Bárbara Melão, MD, PhD @bavilima	Day 1️⃣ @ASCO #GU25 #ProstateCancer #Radioligands #LouiseEmmett ENZA-P, phase 2 trial, mCRPC ✨Enza vs Enza+Lu-PSMA - Adaptive dosing (2-4 doses) ✨Combination Lu-PSMA+Enza improved OS 👉 8 months ✨also improved QoL @MikeSerzanMD @ReneeSa…	Neutral	3,142
Emre Yekedüz @yekeduz_emre	🔥Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901) ⏩ @ASCO #GU25: Adding [177Lu]Lu-PSMA-617 to en…	Positive	2,327
Toni Choueiri, MD @DrChoueiri	New results from ENZA-p trial: adding LuPSMA to enzalutamide improves OS in poor-risk mCRPC (HR 0.55). Also boosts QoL! #ProstateCancer @drlouiseemmett @ASCO #GU25 @OncLive @OncoAlert	Neutral	1,902
Yüksel Ürün @DrYukselUrun	ENZA-P Trial at #GU25 Presented by Louise Emmett, this phase 2 trial explores Lu-PSMA-617 + enzalutamide in mCRPC. 🔹 OS Benefit: Median OS 34 vs. 26 months 🔹 QoL Gains: Less fatigue & pain vs. enzalutamide alone A promising step in PSMA-t…	Neutral	1,245
Jordan Ciuro, MD @jordanciuro	OS updates in ENZA-P trial evaluating Lu-PSMA with enzalutamide in 1L mCRPC? #GU25 ✅Improved OS 26m to 34m w/ enza+Lu-PSMA ✅Improved QOL ✅Grade 3-5 AE 44% enza mono vs 46% in combination 📌More data for earlier PSMA therapy!!! Check out …	Neutral	1,089
Declan Murphy @declangmurphy	Breaking News GU Cast chat with @drlouiseemmett @WeickhardtOnc about ENZA-P OS data released today. Links in thread check out GU Cast for deep dive #gu25 @TheLancetOncol. Amazing benefit to adding LuPSMA to enza @ANZUPtrials @RenuEapen @gu…	Positive	1,069
Zach Klaassen @zklaassen_md	OS and QoL with 177Lu-PSMA-617 + ENZA vs ENZA alone in poor-risk mCRPC in ENZA-p (ANZUP 1901) @drlouiseemmett @urotoday #GU25 ENZA + LuPSMA vs ENZA: ☑️ mOS: 34 mos vs 26 mos, HR 0.55, 95%CI 0.36-0.84 (38% of ENZA mono pts received LuPSMA …	Neutral	963
Dillon Cockrell, MD @DCockrellMD	New data from ENZA-P, phase II trial of 1L enzalutamide +/- Pluvicto for poor risk mCRPC. No chemo for CRPC. rPFS benefit seen previously and continues, now with improved OS (34 vs 26 months). QOL better with combo! More support for earlier…	Neutral	716
Yao Zhu @yao_zhu_sh	The safety profile may guide treatment preference for Talapro-2, Enza-P and PEACE-3. #GU25	Neutral	490
Dr. Iván R. González @Dr_Ivanoncologo	The ENZA-p study (ANZUP 1901) has demonstrated that combining enzalutamide with [177Lu]Lu-PSMA-617 significantly improves survival and quality of life for patients with metastatic castration-resistant prostate cancer. ANZUP #ProstateCancer…	Neutral	240
Tanya Dorff @TDorffOnc	Curious to see differences between 2 doses and 4 doses of 177-Lu-PSMA-617 But very encouraging results, combination therapy will become a new standard for mCRPC	Nuanced	207
Ian Davis @Prof_IanD	Only a small proportion had 2 doses only, but raises the point that on-treatment SPECT can help personalise dosing appropriately. #GU25	Nuanced	62

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Trial 3 · NCT02446405

What do oncologists think of the ENZAMET trial (XTANDI®)?

ENZAMET — Metastatic castration-sensitive (hormone-sensitive) prostate cancer — first-line, with testosterone suppression

FDA-APPROVED SETTING · mCSPC (Dec 2019)Enzalutamide is FDA-approved for metastatic castration-sensitive prostate cancer (approved December 16, 2019, based on the ARCHES trial). ENZAMET is an investigator-initiated (ANZUP) trial providing additional evidence in this FDA-approved setting.

Physicians are broadly favorable, with real nuance on ENZAMET: 0% of 2 verified physician voices positive, 0% nuanced (praising the result while flagging a caveat), 100% neutral, 0% critical.

100%

Positive 0% Nuanced 0% Neutral 100% Critical 0%

Denominator: 2 distinct verified physician voices across 6 oncologist posts, 2026-05-24 to 2026-05-30. Sponsor: University of Sydney / ANZUP Cancer Trials Group

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Primary sources: ClinicalTrials.gov · NCT02446405 · NEJM 2019 — ENZAMET (Davis et al.)

Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 2019 (ENZAMET, NCT02446405).

Physician voices — verbatim

Full physician voice list (2)

Physician	Comment (verbatim)	Sentiment	Impressions
Daniel V. Araujo @dvaraujomd	ENZAMET Decipher analysis (#ASCO26, Abstr 5001). A practical question we deal with constantly: who actually needs docetaxel added to ADT + enza in mHSPC? They ran the Decipher genomic classifier (>0.85 cutoff) on 634 pts from ENZAMET. High…	Neutral	3,399
Toni Choueiri, MD @drchoueiri	presents level 1B evidence from ENZAMET suggesting Decipher GC >0.85 may identify pts deriving benefit from docetaxel intensification alongside ADT + enzalutamide, while no clear benefit signal was observed for GC ≤0.85. #ASCO26 #ProstateCa…	Neutral	2,144

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Regulatory

XTANDI® — FDA status

FDA APPROVEDXTANDI® (enzalutamide) is an androgen receptor inhibitor FDA-approved across multiple prostate-cancer settings — metastatic castration-resistant prostate cancer (initial approval 2012), non-metastatic castration-resistant prostate cancer (2018), metastatic castration-sensitive prostate cancer (2019), and non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence (2023). For the full, current list of FDA indications and prescribing information, see xtandi.com or FDA label (DailyMed). KOL Pulse indexes the physician conversation; the label is owned and maintained by the manufacturer.

Frequently Asked

XTANDI® sentiment — FAQ

EMBARK

What do oncologists think of the EMBARK trial (XTANDI®)?

Across 12 verified physician voices in KOL Pulse's index for EMBARK, 25% expressed positive sentiment, 25% were nuanced (praising the result while flagging a caveat), 33% were neutral, and 17% were critical. Positive voices highlight the metastasis-free-survival benefit of enzalutamide (with leuprolide, or as monotherapy) in high-risk biochemically recurrent, non-metastatic castration-sensitive prostate cancer, and the option to intensify earlier; nuanced and critical voices flag patient selection and over-treatment of biochemical-recurrence-only disease, the toxicity and quality-of-life trade-offs of earlier ARPI exposure, and the monotherapy-versus-combination question.

Where can I find the EMBARK trial data for XTANDI® (enzalutamide)?

EMBARK is registered as NCT02319837 and studied XTANDI® (enzalutamide) in Non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence. KOL Pulse's EMBARK trial profile is coming soon.

ENZA-p

What do oncologists think of the ENZA-p trial (XTANDI®)?

Across 13 verified physician voices in KOL Pulse's index for ENZA-p, 16% expressed positive sentiment, 15% were nuanced (praising the result while flagging a caveat), 69% were neutral, and 0% were critical. Positive voices highlight whether adding the PSMA-targeted radioligand 177Lu-PSMA-617 to enzalutamide improves outcomes in mCRPC, and the role of PSMA imaging as a prognostic/predictive biomarker; nuanced and critical voices flag the phase 2 size and endpoints, the added toxicity and logistics of radioligand therapy, and how the combination fits alongside established enzalutamide use.

Where can I find the ENZA-p trial data for XTANDI® (enzalutamide)?

ENZA-p is registered as NCT04419402 and studied XTANDI® (enzalutamide) in Metastatic castration-resistant prostate cancer — enzalutamide + 177Lu-PSMA-617 (investigational combination). KOL Pulse's ENZA-p trial profile is coming soon.

ENZAMET

What do oncologists think of the ENZAMET trial (XTANDI®)?

Across 2 verified physician voices in KOL Pulse's index for ENZAMET, 0% expressed positive sentiment, 0% were nuanced (praising the result while flagging a caveat), 100% were neutral, and 0% were critical. Positive voices highlight the overall-survival benefit of adding enzalutamide to standard first-line testosterone suppression in metastatic castration-sensitive prostate cancer; nuanced and critical voices flag toxicity and the interaction with early docetaxel, and how ENZAMET's academic design and results align with the ARCHES registration data.

Where can I find the ENZAMET trial data for XTANDI® (enzalutamide)?

ENZAMET is registered as NCT02446405 and studied XTANDI® (enzalutamide) in Metastatic castration-sensitive (hormone-sensitive) prostate cancer — first-line, with testosterone suppression. KOL Pulse's ENZAMET trial profile is coming soon.

Regulatory

Is XTANDI® (enzalutamide) FDA approved?

XTANDI® is FDA-approved. KOL Pulse organizes this page by clinical trial and links out to the manufacturer's brand site and the FDA label for the full, current list of FDA indications and prescribing information — the label is owned and updated by the manufacturer, so we point to it rather than reproducing it.

Methodology

How this index is built

KOL Pulse indexes verbatim posts from verified oncology physicians and rolls sentiment up per clinical trial. Each physician is counted once per trial, at their highest-reach post. Sentiment is classified from the verbatim text (positive / nuanced / neutral / critical), where "nuanced" marks a voice that praises the result while flagging a substantive caveat (immature overall survival, toxicity, or trial-design/selection concerns). Institutional, media, finance, and non-physician accounts are excluded from the denominator. Quotes are reproduced verbatim and attributed to the physician's public post. KOL Pulse organizes this page by clinical trial — the maintainable unit — and links out to the manufacturer's brand site and the FDA label for the full indication list, which the manufacturer owns and updates. Trial efficacy figures are held for medical-expert verification before publication. This page reports the physician conversation; it is not medical advice and does not endorse any product.